BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23539050)

  • 1. Is a legacy effect possible in IgA nephropathy?
    Coppo R
    Nephrol Dial Transplant; 2013 Jul; 28(7):1657-62. PubMed ID: 23539050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy.
    Maeda I; Hayashi T; Sato KK; Shibata MO; Hamada M; Kishida M; Kitabayashi C; Morikawa T; Okada N; Okumura M; Konishi M; Konishi Y; Endo G; Imanishi M
    Nephrol Dial Transplant; 2012 Jul; 27(7):2806-13. PubMed ID: 22492824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.
    Haas M; Jafri J; Bartosh SM; Karp SL; Adler SG; Meehan SM
    Am J Kidney Dis; 2000 Oct; 36(4):709-18. PubMed ID: 11007672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune modulating therapy for IgA nephropathy: rationale and evidence.
    Floege J; Eitner F
    Semin Nephrol; 2008 Jan; 28(1):38-47. PubMed ID: 18222345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C; Andrulli S; Pani A; Scaini P; Roccatello D; Fogazzi G; Pecchini P; Rustichelli R; Finocchiaro P; Del Vecchio L; Locatelli F
    J Nephrol; 2013; 26(1):86-93. PubMed ID: 22460183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.
    Hotta O; Miyazaki M; Furuta T; Tomioka S; Chiba S; Horigome I; Abe K; Taguma Y
    Am J Kidney Dis; 2001 Oct; 38(4):736-43. PubMed ID: 11576876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tonsillectomy with steroid pulse therapy has more effect on the relapse rate than steroid pulse monotherapy in IgA nephropathy patients.
    Ohya M; Otani H; Minami Y; Yamanaka S; Mima T; Negi S; Yukawa S; Shigematsu T
    Clin Nephrol; 2013 Jul; 80(1):47-52. PubMed ID: 23557791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial.
    Locatelli F; Pozzi C; Del Vecchio L; Andrulli S; Pani A; Fogazzi G; Altieri P; Ponticelli C
    J Nephrol; 1999; 12(5):308-11. PubMed ID: 10630693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tonsillectomy does not prevent a progressive course in IgA nephropathy.
    Rasche FM; Schwarz A; Keller F
    Clin Nephrol; 1999 Mar; 51(3):147-52. PubMed ID: 10099887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of IgA nephropathy: a repeat biopsy study.
    Hotta O; Furuta T; Chiba S; Tomioka S; Taguma Y
    Am J Kidney Dis; 2002 Mar; 39(3):493-502. PubMed ID: 11877568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy].
    Sugawara K; Takeda K; Nakai K; Takahashi N; Adachi T; Fukuda T; Miura S
    Nihon Jinzo Gakkai Shi; 2008; 50(8):1017-23. PubMed ID: 19172803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
    Fernandes PF; Júnior GB; Barros FA; Sousa DC; Franco LM; Patrocínio RM
    Invest Clin; 2006 Dec; 47(4):405-11. PubMed ID: 17176908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of IgA nephropathy].
    Amoroso L; De Sanctis L; Cappelli P; Di Vito R; Sirolli V; Bonomini M
    G Ital Nefrol; 2011; 28(6):622-32. PubMed ID: 22167613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM; Poveda R; Ibernón M; Díaz M; Fulladosa X; Carrera M; Torras J; Bestard O; Navarro I; Ballarín J; Romero R; Grinyó JM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C; Del Vecchio L; Locatelli F
    G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
    Chábová V; Tesar V; Zabka J; Rychlík I; Merta M; Jirsa M; Stejskalová A; Stejskal J
    Cas Lek Cesk; 1996 Dec; 135(24):803-6. PubMed ID: 9072300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
    Ferrari P; Frey FJ
    Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of IgA nephropathy: status at the end of the millenium.
    Glassock RJ
    J Nephrol; 1999; 12(5):288-96. PubMed ID: 10630691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of progressive IgA nephropathy: an update.
    Wang W; Chen N
    Contrib Nephrol; 2013; 181():75-83. PubMed ID: 23689569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in primary glomerular disease in 2007].
    Ara J
    Nefrologia; 2008; 28 Suppl 5():85-9. PubMed ID: 18847426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.